Medidata-Sanofi Vaccines Extended Alliance Enhances Patient Centricity, Trial Efficiency

KUALA LUMPUR, Feb 7 (Bernama) -- Medidata, a Dassault Systèmes company, has announced a collaboration with Sanofi Vaccines to harness Medidata electronic Clinical Outcome Assessment (eCOA) to deploy in vaccine studies.

According to a statement, this builds on Medidata and Sanofi’s longstanding, successful experience using Medidata Rave electronic data capture (EDC).

“At Medidata, we put the patient at the core of all of our work, and collaborating with Sanofi, who share this ethos, helps improve patient experience, the monitoring of patients in current studies, and accelerate study timelines and efficiencies in future studies,” said Medidata Patient Cloud chief executive officer, Anthony Costello.

The collaboration will use an eDiary function within eCOA to create an eDiary library specific to Sanofi’s vaccines, in which the library will accelerate future study set-up times, improve efficiency, and increase data quality, while ensuring patients have access to eDiaries that are easy to use.

Sanofi has chosen to adopt eCOA’s capabilities in its vaccine studies, optimising the patient clinical journey by reducing on-site monitoring and allowing patients to input data in real time from any location.

Pilots of eCOA were performed in six vaccine studies and demonstrated high levels of patient compliance, providing highly reliable data.

As a result, the collaboration has since moved out of the pilot phase, with eCOA being deployed across a pipeline of Sanofi’s vaccine clinical trials.

Built as part of the unified Medidata Platform, eCOA is a full-service offering revolutionising the way sponsors, contract research organisations, and sites collect data from patients, physicians as well as caregivers.

A provider of clinical trial solutions to the life sciences industry, Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials.

-- BERNAMA